A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Completed
MyoKardia, Inc.
Phase 2
2018-03-30
This is a multicenter, exploratory, randomized, double-blind study of the administration of
mavacamten in 60 participants with symptomatic nHCM randomized to receive a 16-week course of
mavacamten doses titrated to achieve 1 of 2 target drug concentrations.
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Completed
MyoKardia, Inc.
Phase 3
2018-05-29
This is a multicenter, international, double-blind study of the administration of mavacamten
in participants with symptomatic obstructive HCM (oHCM). Approximately 220 participants will
be randomized to receive placebo or mavacamten.
Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
Active, not recruiting
MyoKardia, Inc.
Phase 2
2018-04-26
This is a multicenter open-label study of the administration of mavacamten in participants
with symptomatic obstructive HCM (oHCM) who previously participated in study MYK-461-004
(PIONEER-HCM).
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
Enrolling by invitation
MyoKardia, Inc.
Phase 2/Phase 3
2018-10-05
Approximately 30 sites that enrolled participants in the MAVERICK-HCM (MYK-461-006) study in
the United States (US) will initiate this study.
Approximately 90 sites that enrolled participants in the EXPLORER-HCM (MYK-461-005) study in
the US, Europe, and Israel will initiate this study.
Note: Approximately 30 centers overlap between MAVERICK and EXPLORER.
A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
Active, not recruiting
MyoKardia, Inc.
Phase 3
2020-06-26
This is a randomized, double-blind, placebo-controlled, multi-center study in the United
States (U.S.) that will evaluate the effect of mavacamten treatment on reducing the number of
septal reduction therapy (SRT) procedures performed in subjects with symptomatic obstructive
hypertrophic cardiomyopathy (oHCM [also known as HOCM]) who are eligible for SRT based on
ACCF/AHA 2011 and/or ESC 2014 guidelines.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
